

Novel hIL-4 mutant proteins as antagonists or partial agonists of human interleukin 4

Abstract

The present invention relates to novel hIL-4 mutant proteins, to processes for preparing them, and to their use as medicaments, in particular in overshooting, falsely regulated immune reactions and autoimmune diseases.